ClinicalTrials.gg
RecruitingNCT07672223Updated Nov 12, 2026

A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of SYS6010 and Enlonstobart in Non-small Cell Lung Cancer, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 12, 2026Now RecruitingFirst site in China+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
586
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited — 11 open to participants now, 12 under way, 7 of them phase 3. Carcinoma, Non-Small-Cell Lung · CSPC Pharmaceutical Group Limited.

Planned enrollment
2nd of 16
586 · median 365
Started
2026
with 3 others
Phase 3
7 of 17
6 open now
Primary completion
2029-09
later than 11 of 11 live
Registered
17th of 17
by date

Among the 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited, this one is the 2nd largest by planned enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2026, is one of 7 in phase 3, reaches primary completion later than 11 of the 11 other live ones, and was the 17th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

11 of the 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited, or all of them as a file.
02

Study summary

The purpose of the study is to compare the efficacy and safety of SYS6010 in combination with anti-PD-(L)-1 monoclonal antibody vs. anti-PD-(L)-1 monoclonal antibody as adjuvant therapy for patients with. with completely resected stage II-IIIB, actionable genomic alterations (AGAs) negative non-small cell lung cancer (NSCLC) who did not achieve a major pathological response (MPR).

Read the detailed description

This is a randomized, open-label, multicenter, Phase III clinical study. Participants with completely resected stage II-IIIB, actionable genomic alterations (AGAs) negative non-small cell lung cancer (NSCLC) who did not achieve a major pathological response (MPR) will be enrolled and randomized in a 1:1 ratio to experimental (SYS6010 + Enlonstobart) or control (Investigator's Choice of anti-PD-(L)-1 Monoclonal Antibody Regimen) group. Random factors include disease stage (Stage II / IIIA vs. Stage IIIB), Pathological type (non-squamous cell carcinoma vs. squamous cell carcinoma), and lymph node status (positive vs. negative).

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and willingness to voluntarily provide written .
  2. Age 18 to 75 years, males or females.
  3. confirmed squamous or non-squamous NSCLC.
  4. Ability to provide qualified tumor samples.
  5. Without actionable genomic alterations (AGAs), which should be tested at a local or central laboratory.
  6. Did not achieve a Major Pathological Response (MPR) as assessed by the Central Pathology Independent Review Committee (CPIRC).
  7. The International Association for the Study of Lung Cancer (IASLC) V9 Stage II-IIIB NSCLC, after confirmed complete surgical resection with resection margins proved microscopically free of disease (R0).

Exclusion criteria

Exclusion Criteria:

  1. Participants with a condition requiring further surgical resection, in the investigator's opinion.
  2. Participants with diagnosis of stage IIIB with N3, and stage IIIC, IVA, and IVB NSCLC.
  3. Eligible only for incomplete resection.
  4. Participants with synchronous primary lung cancer or multiple primary , or a mixed histology of SCLC and NSCLC.
  5. History of or to any active or inactive of the study treatment.
  6. Prior or planned or adjuvant radiotherapy for the current malignancy.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
586 participants (estimated)

Study arms

  • Experimental
    SYS6010 + Enlonstobart

    Drug: SYS6010 · Drug: Enlonstobart

  • Active comparator
    Investigator's Choice of anti-PD-(L)-1 Monoclonal Antibody Regimen

    Drug: Tislelizumab · Drug: Toripalimab ±+platinum-based doublet chemotherapy · Drug: Durvalumab · Drug: Pembrolizumab · Drug: Nivolumab

Interventions

  • SYS6010

  • Enlonstobart

    Also known as: SG001

  • administered via Intravenous (IV) injection

    Also known as: BGB-A317

  • DrugToripalimab ±+platinum-based doublet chemotherapy

    Cisplatin; Carboplatin; Pemetrexed; Paclitaxel;

    Also known as: Cisplatin; Carboplatin; Pemetrexed; Paclitaxel;

  • Durvalumab

    Also known as: MEDI4736

  • Pembrolizumab

    Also known as: KEYTRUDA® MK-3475

  • Nivolumab

    Also known as: Opdivo, BMS936558S

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS) assessed by the independent review committee (IRC)

    DFS was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by IRC per RECIST 1.1 or death (whatever the cause). Recurrence of disease was defined as local regional recurrence or a distant (metastatic) recurrence, confirmed by imaging and/or pathology. A second primary NSCLC was also considered to be an event.

    Time frame: Up to approximately 60 months

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to the date of death(whatever the cause).

    Time frame: Up to approximately 60 months

  2. DFS assessed by investigators

    DFS was defined as the time from randomization to either the date of disease recurrence as assessed by investigators per RECIST 1.1 or death (whatever the cause). Recurrence of disease was defined as local regional recurrence or a distant (metastatic) recurrence, confirmed by imaging and/or pathology. A second primary NSCLC was also considered to be an event.

    Time frame: Up to approximately 60 months

  3. Incidence and severity of Adverse Events (AEs)

    Time frame: Approximately 15 months

  4. EORTC QLQ-30 questionnaire

    Time frame: Approximately 13 months

  5. Blood concentration of SYS6010 and Enlonstobart

    Time frame: Approximately 13 months

  6. Anti-drug Antibodies (ADAs) and Neutralizing Antibodies (Nabs)

    Time frame: Approximately 13 months

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Sep 2029, 38 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 38 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2026
First posted
Jun 26, 2026
StartActual
Jul 30, 2026was Jun 2026
Primary completionEst.
Sep 30, 2029
CompletionEst.
Nov 30, 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
2 sites added — first site in China
Show 2 added (2 China)
  • Shanghai Chest Hospital · Shanghai, China
  • Shanghai Pulmonary Hospital · Shanghai, China
Nov 12, 2026
Start date
Jun 25, 2026→Jul 30, 2026 (actual)
Nov 12, 2026
Enrollment
570→586
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in China
    Show 2 added (2 China)
    • Shanghai Chest Hospital · Shanghai, China
    • Shanghai Pulmonary Hospital · Shanghai, China
    Start date Jun 25, 2026→Jul 30, 2026 (now actual)
    Enrollment 570→586
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07672223
Responsible party
Sponsor
First posted
Jun 26, 2026
Start date
Jul 30, 2026
Primary completion
Sep 30, 2029 (estimated)
Completion
Nov 30, 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
031169085587

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-EGFR Antibody-drug Conjugate CPO301 · Enlonstobart

Start the discussion